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Abstract
Murine collagen-induced arthritis (mCIA) is characterized by decreased vascu-
lar constriction responses and increased MMP-9. Here, we describe additional
histological alterations within the aorta and surrounding perivascular adipose
tissue (PVAT), study the role of PVAT in constriction response, and investi-
gate the potential involvement of death receptor 3 (DR3). mCIA was induced
in wild-type (WT) and DR3/ mice with nonimmunized, age-matched con-
trols. Vascular function was determined in isolated aortic rings PVAT, using
isometric tension myography, in response to cumulative serotonin concentra-
tions. Cellular expression of F4/80 (macrophages), Ly6G (neutrophils), DR3,
and MMP-9 was determined using immunohistochemistry. In WTs, arthritis-
induced vascular dysfunction was associated with increased F4/80+ macro-
phages and increased DR3 expression in the aorta and PVAT. MMP-9 was
also up-regulated in PVAT, but did not correlate with alterations of PVAT
intact constriction. DR3/ mice inherently showed increased leukocyte num-
bers and MMP-9 expression in the PVAT, but retained the same nonarthritic
constriction response as DR3WT mice PVAT. Arthritic DR3/ mice had a
worsened constriction response than DR3WT and showed an influx of neu-
trophils to the aorta and PVAT. Macrophage numbers were also up-regulated
in DR3/ PVAT. Despite this influx, PVAT intact DR3/ constriction
responses were restored to the same level as DR3WT. Impaired vascular con-
striction in inflammatory arthritis occurs independently of total MMP-9
levels, but correlates with macrophage and neutrophil ingress. Ablating DR3
worsens the associated vasculature dysfunction, however, DR3/ PVAT is
able to protect the aorta against aberrant vasoconstriction caused in this
model.
Abbreviations
CV, cardiovascular; CVD, cardiovascular disease; DR3, death receptor 3; DR3/,
death receptor 3 knockout; DR3WT, death receptor 3 wild type; fTreg, fat resident
regulatory T cell; MMP-9, matrix metalloproteinase 9; mAB, monoclonal antibody;
mCIA, murine collagen-induced arthritis; NO, nitric oxide; PVAT, perivascular
adipose tissue; RA, rheumatoid arthritis; Treg, regulatory T cells; SPM, specialized
pro-resolving mediators; WT, wild type.
Introduction
Rheumatoid arthritis (RA) is a risk factor for cardiovascu-
lar (CV) disease (CVD). Indeed, RA patients are twice as
likely to suffer a CV death than age-matched healthy
individuals (Solomon et al. 2006); (Roman and Salmon
2007). Coronary artery disease is one of the most com-
mon causes of death in RA patients and its risk is evident
even before a clinical RA diagnosis (Maradit-Kremers
et al. 2005). The cause of increased risk of CVD for RA
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patients is not well defined. However, an association
between RA, high lipid profiles, and underlying levels of
systemic inflammation have recently been identified
(Myasoedova et al. 2010).
A role for innate immune cells, such as macrophages
and neutrophils, in the pathogenesis and progression of
RA is long standing and well defined (Koch et al. 1994);
(Kinne et al. 2000). Whether the presence of these cells
impacts on the vasculature contributing to associated
CVD remains in question, even though the presence of
these cells in the aortic vessel wall and surrounding
perivascular adipose tissue (PVAT) has been postulated
since 1986 (Jonasson et al. 1986). It is known that the
number of macrophages is able to increase in PVAT and
is dependent on factors such as age, nutritional status,
and local environment (Skilton et al. 2009). Thus, we
describe the impact of systemic inflammation on these
cellular populations in both the vasculature and the sur-
rounding PVAT.
To mechanistically investigate these tissues in human
disease is difficult, if not, impossible. Thus, this “proof-of-
concept” study uses an appropriate surrogate animal
model. With regard to looking at early systemic inflamma-
tory changes in relation to RA, murine collagen-induced
arthritis (mCIA) is a well described and characterized
model (Hegen et al. 2008). We have previously used the
mCIA model to characterize vascular responses in early
RA, describing decreased constriction responses associated
with increased aortic matrix metalloproteinase 9 (MMP-9)
(Reynolds et al. 2012). MMP-9 is a key mediator involved
in degradation of the extracellular matrix during the
remodeling process that occurs “normally” in the vascula-
ture. However, it is often inappropriate remodeling, driven
by increase in proteins such as MMP-9 and decrease in
their inhibitors that underpins CV pathology (Janssens
and Lijnen 2005). Given the reported role of immune cells
in the production of MMP-9 in a dysfunctional vascula-
ture (Rizas and Ippagunta 2009); (Zhang et al. 2011) and
the potential function of such cells in RA, further charac-
terization of the vascular phenotype in mCIA would pro-
vide insight into the association between RA and CVD.
An important signaling molecule, death receptor 3
(DR3), has been linked to the differentiation of macro-
phages to the foam cells that populate atherosclerotic pla-
que (McLaren et al. 2010), neutrophil accumulation in
arthritic joints, and increased MMP-9 production in
inflammatory arthritis (Wang et al. 2014). DR3 is the clos-
est relative to TNFR1, the receptor for TNFa. It can signal
both cell death via its intracellular death domain and cell
survival via activation of transcription factor NF-jb
(Kitson et al. 1996); (Marsters et al. 1996). DR3 has one
known TNFSF ligand – TNF like protein 1 A (TL1A)
(Migone et al. 2002), a close relative of TNFa (Jin et al.
2007), a master regulator of inflammation that is up-regu-
lated in RA (Feldmann and Maini 2003). Interestingly, in
the antigen-induced model of arthritis, DR3 knockout
(DR3/) mice exhibit a decrease in the articular popula-
tion of neutrophils, compared to wild type (WT) (Wang
et al. 2014). Whether DR3 modulates or contributes to the
vascular dysfunction in RA is an obvious area for further
study.
The aim of this study was to explore the causes of
decreased vascular constriction in mCIA. The presence of
inflammatory cells in both the aortic vessel wall and PVAT
of arthritic and normal tissues were determined. Focus was
directed to macrophages, neutrophils, and total MMP-9
production. The impact of ablation of DR3 expression on
these measurements was also investigated. For the first time,
we establish a relationship between experimental arthritis
onset and the nature and extent of immune cell ingress into
the aortic vessel wall and PVAT, and describe protection
from vascular dysfunction in the absence of DR3.
Materials and Methods
Animals
Male mice (8 weeks old) were used for all experiments.
WT DBA/1 mice were acquired from Harlan, UK. DBA/1
DR3 knockout (DR3/) and appropriately age-matched
DBA/1 DR3 WT mice (DR3WT) were sourced from an
in-house breeding colony, generated by DR3het 9 DR3het
crossing. The DBA DR3/ colony was produced through
backcrossing C57Bl/6het mice with DBA/1 WT mice for
seven generations. All animal care and experimental
procedures complied with the United Kingdom Animals
(Scientific Procedures) Act 1986 and were under the
authority of Home Office Project Licence (30/2928).
Induction of mCIA
mCIA was induced as previously described (Nowell et al.
2009; Reynolds et al. 2012). In brief, mice were immu-
nized on two occasions, 21 days apart, with identical
100 lL intradermal injections of an emulsion containing
1 mg/mL type II chicken sternal collagen (Sigma, Dorset,
UK) and 2.5 mg/mL Freund’s complete adjuvant. Tem-
gesic (0.4 mg/mL) was administered ad libitum via the
drinking water on day 20 before arthritis onset and was
continued until the end of each experiment.
Assessment of arthritis
Joint swelling was assessed (under isoflurane) daily
following immunization on day 21 as previously described
(Reynolds et al. 2012). Hind paw swelling was recorded
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for both paws using an analog micrometer. Each paw was
also scored 0–5 (Table 1) dependent on arthritis onset
and a combined paw score was used to determine total
severity; mild arthritis (1–5), moderate arthritis (6–9),
and severe arthritis (10–14).
Collection of experimental samples
At experimental end point, defined as a combined paw
score of up to 5 (mild arthritis) or at day 29 for
DR3WT versus DR3/ experiments, mice were killed
by inhalation of CO2. Subsequently, the aorta was
exposed and vented in the abdominal region. The left
ventricle was then perfused with 500 lL of physiological
Krebs solution (mmol/L: NaCl 10.92, KCl 2.68, KH2PO4
1.78, MgSO4.7H2O 2.49, NaHCO3 25.10, glucose 10.99,
CaCl2.2H20 1.98). The thoracic aorta was dissected
from the animal with PVAT intact and immediately
placed in iced Krebs solution for myography. Alterna-
tively, tissues isolated for use in histology and QPCR
were fixed/stored in 70% (w/v) ethanol (minimum of
1 week at 4°C) or “RNA later” (overnight at 4°C fol-
lowed by long term storage at 20°C), respectively.
Not all tissues from all animals were used for all
experiments.
Determination of vascular constriction
Myography was used to investigate vascular constriction
to serotonin (5-HT) in isolated sections of thoracic aorta
in the absence () or presence (+) of PVAT. Such experi-
ments have been previously described (Cai et al. 2005;
Reynolds et al. 2012). Aortic rings (2 mm thick) from
nonarthritic control and mild arthritic mice were bathed
in physiological Krebs solution at 37°C and gassed with
95% O2/5% CO2. Each ring was set to a baseline tension
of 5 mN. Following equilibration, rings were exposed to a
“wake up response” of 60 mmol/L potassium Krebs
(mmol/L: NaCl 39.36, KCl 59.83, KH2PO4 1.18,
MgSO4.7H2O 2.49, NaHCO3 25.10, glucose 10.99,
CaCl2.2H20 1.98). Once constriction had reached a
plateau, tissues were washed and allowed to return to
baseline tension. Cumulative concentration responses to
5-HT (1 nmol/L–10 mmol/L) were then carried out. Tis-
sue contractile response was measured using MyoDak
software and analyzed using MyoData and was calculated
as developed tension in mN.
Histological evaluation of the aortic vessel
and PVAT
Following fixing, samples were processed in the Shandon
tissue processor before paraffin wax blocks were formed.
Sections, 8 lm in thickness, were cut using a microtome
and placed onto Superfrost+ slides and kept at 70°C over-
night. Each section was rehydrated, stained using hema-
toxylin (1 min) and eosin (30 sec), before being
dehydrated and mounted using DPX. Images at 910
magnification were acquired using a Leica microscope
and camera and were analyzed using Image J and Care-
stream software.
Protein identification by immunohisto-
chemistry
Immunohistochemistry was used to visualize protein
markers (F4/80 (macrophages), Ly6G (neutrophils), DR3,
and total MMP-9) within the aortic vessel wall and sur-
rounding PVAT. A standard protocol was used for each,
with specific antibodies for individual targets. In brief,
sections were rehydrated and blocked for endogenous
peroxidase, avidin, and biotin activity. Rat anti-mouse F4/
80 (Abcam, Cambridge, UK) and Ly6G (BD Pharmigen,
Oxford, UK) was used at 2 and 1 lg/mL, respectively
with a secondary rabbit anti-rat IgG antibody (Vector
Labs, Peterborough, UK). For both DR3 and MMP-9
expression, specific biotynylated goat anti-mouse antibod-
ies (R&D Systems, Abingdon, UK) were used at 2 and
15 lg/mL, respectively. Appropriate isotypes were used
for each antibody. Positive protein identification was
determined using a streptavidin–HRP conjugate and DAB
chromogen in all cases. Sections were then counterstained
with hematoxylin before being dehydrated and mounted
with DPX. High-power images at 940 magnification were
taken with a Leica microscope and camera and analyzed
using Photoshop.
All immunohistochemical analysis was performed blind.
Total cells were counted using a computer program called
Living Image, in which, each cell was detected by “edge”
(the computer identifies changes in color to find the
edges of each cell nuclei). The computer automatically
detects each cell nuclei in a given area. Percentage of pos-
itive staining refers to the staining intensity overall, within
the given region.
Table 1. Paw scoring system.
Paw score Pathological features
0 Normal
1 Mild/moderate erythema and swelling (single toes
effected with no other swelling)
2 Severe swelling encompassing whole paw
3 Severe swelling encompassing the whole paw, and
toes beginning to become effected
4 Whole paw/ankle/toes swollen
5 Deformed paw/ankylosis
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Statistical analysis
Data are expressed as mean  SEM, n ≥ 4 for all experi-
ments. Not all animal samples were used for each experi-
ment. Constriction response data are expressed as
developed tension in mN and was fitted to a sigmoidal
curve using GraphPad Prism. Rmax and EC50 values
were calculated for each response curve to determine the
concentration that produced maximal and half maximal
constriction. All data were compared using Student’s
t-tests and a significant difference was considered as
P < 0.05.
Results
The presence of PVAT impacts both normal
and arthritic vascular constriction responses
As previously described by Reynolds et al. (2012), we
showed significantly (P < 0.001) depressed maximal con-
striction responses of arthritic aortic tissue -PVAT follow-
ing exposure to 5-HT (4.40  0.05 mN, n = 14), in
comparison to nonimmunized control tissue
(5.56  0.06 mN, n = 8). No differences in EC50 values
were observed (Fig. 1).
For the first time, the impact of the presence of PVAT
on the arthritic vascular constriction response was also
investigated. In both arthritic (n = 13) and
nonimmunized control (n = 8) aorta, PVAT caused sig-
nificant (P < 0.001) dextral shifts in the constriction
responses to 5-HT, altering EC50 (5.98  0.02 mN vs.
6.13  0.04 mN) (Fig. 1). Maximal constriction was
not impacted by PVAT and remained significantly
(P < 0.05) decreased in arthritic tissue compared to
nonimmunized controls (4.96  0.06 mN vs. 5.43 
0.10 mN).
Decreased constriction response following mCIA onset
was further evaluated to determine inflammatory context
of the aortic vessel wall and PVAT. Hematoxylin and
eosin staining highlighted the different structure of the
vessel wall and PVAT following arthritis onset (Fig. 1).
Despite the total cell number within the PVAT remaining
unchanged, the composition of the PVAT between non-
immunized and arthritic animals appears different. Non-
immunized PVAT would seem to consist of white
adipocytes, with a single cell nucleus and a large adipo-
cyte vesicle. However, within arthritic PVAT, cells look
densely packed and have smaller fat-filled vesicles, more
indicative of a brown fat phenotype.
Inflammatory cell infiltration increases in
both the aortic vessel wall and PVAT in
inflammatory arthritis
Characteristic signs of inflammation were observed in the
aortic vessel wall following induction of mCIA (Fig. 2).
Figure 1. The impact of wild-type arthritis on constriction response  perivascular adipose tissue (PVAT). Constriction responses to 5HT were
determined using myography in aortic rings of non-immunized control aorta compared with arthritic aorta; +PVAT (Arthritic N = 13, control
N = 8) and –PVAT (Arthritic N = 14, control N = 8). (A) and (B) show comparison of EC50 within 5HT response curves; non-immunized +PVAT
versus –PVAT and mild arthritic aorta +PVAT versus PVAT respectively. Representative images show hematoxylin and eosin staining of aortic
vessel wall and PVAT of non-immunized controls (C) and arthritic aorta (D). Both maximal constriction and EC50 were compared using an
unpaired t-test. ***P < 0.001. SEM bars are shown in one direction. Images are taken at 920 magnification. Scale bars represent 0.25 lm.
V represents aortic vessel wall and PVAT represents surrounding perivascular fat. (A, B) Key; Non-Immunized, +PVAT (□), –PVAT (■). Mild Arthritis
+PVAT (◊), PVAT (♦).
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In mild mCIA, the number of macrophages, as estimated
by F4/80 signal, was significantly (P < 0.05) increased when
compared to nonimmunized controls (11.2  3.2%,
n = 15 vs. 4.8  0.6%, n = 8; Fig. 2A). For the first time,
we show that this macrophage ingress was associated with
an increased DR3 signal, in the absence of atheroma,
during inflammatory arthritis (9.8  1.7%, n = 8 vs.
5.0  0.5%, n = 13) (P < 0.01, Fig. 2). However, neither
MMP-9 (12.5  3.1%, n = 12 vs. 5.3  3.1%, n = 4),
total leukocyte number (10424  1328 cells/mm2, n = 8
vs. 11438  608 cells/mm2, n = 21), nor neutrophil num-
bers as estimated by Ly6G signal (0.6  0.2%, n = 10 vs.
1.9  0.9%, n = 4) were significantly increased following
arthritis onset (data not shown).
PVAT was analyzed separate from the aortic vessel wall to
investigate whether unique differences could be associated
with the dextral shift in vascular constriction response. A
similar inflammatory profile was observed in the surround-
ing PVAT as to that seen in the aortic vessel wall. F4/80+
macrophage staining was significantly (P < 0.05) increased
in mild disease when compared to nonimmunized controls
(8.8  2.4%, n = 15 vs. 3.1  0.6%, n = 8) and this was
again mirrored by significantly (P < 0.05) increased DR3
expression in mild arthritis (10.2  2.5%, n = 14 vs.
5.8  0.8%, n = 8). Unlike the aorta, a significant
(P < 0.05) increase in total MMP-9 was observed in the
arthritic PVAT (27.2  4.9%, n = 11 vs. 7.0  6.6%,
n = 4) (Fig. 2F). Total leukocyte numbers (6856  743
cells/mm2, n = 8 vs. 5821  453 cells/mm2, n = 21) and
neutrophils (%Ly6G+: 1.8  1.1%, n = 9 vs. 1.6  0.9%,
n = 4) remained unchanged when comparing mild arthritic
PVAT with nonimmunized PVAT (data not shown).
Figure 2. Inflammation-associated changes in the aortic vessel wall and surrounding perivascular adipose tissue (PVAT). Following the onset of
murine collagen-induced arthritis macrophage ingress (A) and DR3 expression (D) are significantly increased in the aortic vessel wall, compared to
non-arthritic controls, however, MMP-9 expression remains unchanged (G). In the PVAT, macrophage (B) and DR3 expression (E) along with
MMP-9 expression (H) was increased in arthritic animals in comparison to non-arthritic controls. Representative images show examples of F4/80
(G), DR3 (H), and MMP-9 (I) staining in nonarthritic and arthritic aorta and PVAT. Images are taken at 940 magnification and scale bars represent
0.2 lm. Unpaired t-tests were used for all shown comparisons. *P < 0.05, **P < 0.01. Error bars represent SEM. N number was at least eight in
arthritic group compared with a minimum of four controls.
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DR3 expression influences cellular infiltrate
in PVAT, but not vascular constriction, in the
absence of arthritis
The association between altered constriction responses
and an increase in DR3 expression in both the aorta and
surrounding PVAT (Fig. 2) suggested that the DR3/TL1A
pathway could be involved in regulating vascular func-
tion. This was tested by exploring DR3/ tissue using
the same readouts. The ablation of DR3 had no impact
on the vascular constriction response seen to 5-HT. Rmax
was similar in DR3/ and DR3WT mice +PVAT
(2.21  0.79 mN, n = 10 vs. 2.22  0.86 mN, n = 10)
and –PVAT (3.82  1.13 mN, n = 10 vs. 3.71 
1.14 mN, n = 10) (Fig. 3). A dextral shift in the constric-
tion response curve to 5-HT was again observed in the
presence of PVAT. This data indicate that DR3 expression
does not intrinsically alter the responses of the aortic vas-
culature.
These results were mirrored by minimal impact on cellu-
lar infiltrate within the aortic vessel wall (Fig. 3). DR3/
mice showed similar numbers of F4/80 + macrophages
(3.6  0.8%, n = 9 vs. 5.2  0.8%, n = 11), MMP-9
expression (13.6  1.7%, n = 16 vs. 11.3  2.8%, n = 14),
and total leukocytes (10968  307 cells/mm2, n = 19 vs.
12142  606 cells/mm2, n = 17) in comparison to DR3WT
mice.
More interestingly, the PVAT of the healthy DR3/
mice had significantly (P < 0.05) higher total leukocyte
counts (7578  346 cells/mm2, n = 19) compared to
DR3WT controls (5695  489 cells/mm2, n = 17). Total
MMP-9 production was also significantly (P < 0.01)
increased in the PVAT of DR3/ (25.7  3.5%, n = 19),
when compared to DR3WT, mice (12.3  2.2%, n = 17)
Figure 3. The impact of DR3 and vascular constriction and inflammation in the aorta and perivascular adipose tissue (PVAT). Ablation of DR3 has
no inherent impact on vascular constriction +PVAT (A) or –PVAT (B). The ablation of DR3 increases total leukocyte number in the PVAT (C), as
seen by representative hematoxylin and eosin staining between DR3 wild type (WT) and DR3/ (D). Total MMP-9 production (E) is also increased
in the PVAT of DR3/. Representative images are provided of MMP-9 immunohistochemistry in DR3 WT and DR3/, with suitable isotype
control (F). Unpaired t-tests were used for all shown comparisons. *P < 0.05, **P < 0.01. SEM bars are shown in one direction. Images are taken
at 920 (Total Cells) and 940 (MMP-9) magnification. Scale bars represent 0.2 lm. N numbers were at least 9 for DR3/ and was compared to a
minimum of 10 DR3 WT. (A, B) Key; DR3WT (■), DR3/ (•).
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(Fig. 3). Macrophage numbers (%F4/80+: 1.9  0.5%,
n = 9 vs. 2.8  0.6%, n = 11) remained unchanged,
when DR3/ mice were compared with DR3WT. This
suggests that DR3, in the absence of inflammation, intrin-
sically regulate cellular infiltration specifically into the
PVAT, although this does not influence the vascular con-
striction responses.
In the absence of DR3, inflammation alters
the cellular infiltrate into aorta but not
PVAT
Experiments were then performed on DR3/ mice in
which CIA had been induced. Following arthritis onset,
DR3/ LY6G+ neutrophil signal in the aorta was signifi-
cantly (P < 0.05) increased in comparison with arthritic
DR3WT mice (1.8  0.5%, n = 4 vs. 0.4  0.2, n = 6)
(Fig. 4). However, F4/80+ macrophage numbers (7.4 
1.7%, n = 8 vs. 8.0  2.7%, n = 6), MMP-9 production
(14.4  2.8%, n = 8 vs. 11.7  3.2%, n = 5), and total
leukocyte number (2088  478 cells/mm2, n = 8 vs.
2042  348 cells/mm2, n = 5) remained unchanged.
Characteristic signs of inflammation were seen in the
PVAT with a significant (P < 0.05) increase in neutrophil
number observed in arthritic DR3/ compared with
DR3WT mice (1.8  0.4%, n = 6 vs. 0.5  0.1%, n = 5)
(Fig. 4). Macrophage number was also significantly
(P < 0.01) increased in arthritic DR3/ (%F4/80+:
Figure 4. The role of DR3 in murine collagen-induced arthritis-associated vascular changes. Vascular constriction responses to 5HT were
compared for DR3 wild type (WT) (•) versus DR3/ (▪), + perivascular adipose tissue (PVAT) (A) and –PVAT (B). Macrophage number remained
consistent between DR3 WT and DR3/ in the aortic vessel wall (C), however, were increased in the PVAT of DR3/ (D). Representative images
(E) are shown of positive macrophage staining in the aortic vessel wall and PVAT, with appropriate isotype control. The number of neutrophils
was increased in both the aortic vessel wall (F) and the PVAT (G) of DR3/ in comparison to DR3 WT. Representative images (H) show positive
neutrophil staining in aortic vessel wall and PVAT, with appropriate isotype control. Unpaired t-tests were used for all shown comparisons.
*P < 0.05, ***P < 0.001. Error bars represent SEM and are shown unidirectional. Images are taken at 940 magnification (Macrophages) and 920
(Neutrophils). Scale bars represent 0.2 and 0.25 lm, respectively. A minimum of six arthritic DR3/ was compared with at least five arthritic DR3
WT.
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27.2  4.4%, n = 5) when compared to arthritic DR3WT
mice (14.0  1.9%, n = 8) (Fig. 4). Total leukocyte num-
bers (1425  245 cells/mm2, n = 8 vs. 1726  348 cells/
mm2, n = 5) and MMP-9 (34.4  2.8%, n = 7 vs.
18.2  6.5%, n = 5) production remained unchanged.
During inflammatory arthritis, DR3/ tissue
exhibit impaired vascular responses only in
the absence of PVAT
Following arthritis onset and exposure to 5-HT, Rmax
values for DR3/ arthritic aortic tissue PVAT
(3.53  0.16 mN, n = 10) were significantly depressed
(P < 0.001) in comparison to arthritic DR3WT tissues
(4.94  0.21 mN, n = 10). No differences in EC50 values
were observed (Fig. 4). Intriguingly, the presence of
PVAT restored the DR3/ maximal constriction to the
same level as DR3WT (4.59  0.34 mN, n = 10 vs.
3.96  0.20 mN, n = 10).
Discussion
The increased risks to health associated with systemic
inflammatory diseases such as RA and CVD are well
established, however, the underlying mechanisms linking
these disorders to clinical events is poorly understood.
Here, we show that systemic inflammation leads to an
impaired vascular constriction response that is impacted
by the presence of PVAT. DR3 is involved in the vascular
constriction response and PVAT modulates this response.
Finally, all of these processes are associated with alter-
ations in the cellular infiltrate into both the aorta and
PVAT.
Vascular contractile dysfunction in mCIA in the
absence of PVAT has been described previously (Reynolds
et al. 2012), but this study demonstrates for the first time
that PVAT caused a general dextral shift in response to 5-
HT in both control and mCIA settings, with maximal
responses being similar to those without PVAT (Fig. 1).
While the implication is that PVAT does not alter its
function in a mCIA setting, this builds on an increasing
body of evidence that PVAT is not just an inert fat store
providing physical protection to the vasculature, but that
it plays a major role in the modulation of vascular con-
striction responses (Lo¨hn et al. 2002); (Verlohren et al.
2004). PVAT produces factors that modulate both vaso-
constriction and relaxation (Gao et al. 2006), behaving
differently according to its immediate environment and
responding to the onset of local inflammation and
hypoxia (Greenstein et al. 2009).
We further investigated the impact of DR3 expression
in this system because signaling through this TNFRSF
member has been shown to modulate 5-HT expression in
the brain (Twohig et al. 2010), as well as being essential
for the progression of inflammatory arthritis in the
periphery. In mCIA, animals treated with antagonistic
anti-TL1A mAb (Bull et al. 2008) and those on a
TL1A/ background show ameliorated disease (Wang
et al. 2013), while the addition of TL1A worsens clinical
and histopathological scores (Zhang et al. 2009). This is
also true in Antigen Induced Arthritis (AIA), where
DR3/ mice are being protected from bone erosions
(Bull et al. 2008) and cartilage destruction (Wang et al.
2014). Addition of TL1A also exacerbates AIA in a dose-
and DR3-dependent manner (Bull et al. 2008). This
essential requirement in murine arthritis models is sup-
ported by data from human disease where increased
TL1A concentrations are found in the serum and synovial
fluid of RA patients, and are linked with autoantibody
production (Zhang et al. 2009).
Our data show that the role of DR3 in vascular con-
striction seems more ambiguous. In the absence of
inflammation, DR3/ constriction responses were com-
parable with DR3WT with or without PVAT (Fig. 3),
suggesting no role in constriction in a healthy setting. In
contrast, although DR3/ mice were protected from
arthritic pathology, their constriction response without
PVAT was far worse than their DR3WT counterparts,
indicating that DR3 was generally protective in the vascu-
lature during systemic inflammation. Even more intrigu-
ingly, the addition of DR3/ PVAT returned DR3/
constriction to DR3WT levels (Fig. 4), demonstrating that
DR3/ PVAT has a vasoconstricting effect. This is simi-
lar to WT PVAT function following the establishment of
obesity where production of oxidative and inflammatory
factors increase contractility (Agabiti-Rosei et al. 2014),
but opposite to WT PVAT’s vasorelaxant role in an
inflammatory setting.
It is clear from this data that the constitution of the
tissues surrounding the vasculature (PVAT and aortic
wall) will likely determine its functional responsiveness.
As a potential effector molecule capable of degrading
stromal tissue and impacting on contractility through its
gelatinase and collagenase activity, we first chose to study
MMP-9. Primarily, MMP-9 was chosen because of previ-
ous reports that described; firstly, increased levels associ-
ated with vascular dysfunction in mCIA (Reynolds et al.
2012), secondly, the capacity of DR3 signaling to trigger
MMP-9 release from macrophages in vitro (Kang et al.
2005); (Collins et al. 2015), and finally, the reduced levels
of MMP-9 observed in the absence of DR3 in AIA (Wang
et al. 2014). MMP-9 levels were increased in PVAT, but
not the aortic wall, of WT mice undergoing mCIA
(Fig. 2). Surprisingly, MMP-9 was also up-regulated in
the PVAT of healthy DR3/ mice. Defining the underly-
ing reasons behind this will require further study, as
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many cell types can produce MMP-9; ranging from
macrophages, neutrophils, and fibroblasts (Wang et al.
2014) to adipocytes (Bouloumie´ et al. 2001), mast cells
(Kanbe et al. 1999), and mesenchymal stem cells. Many
of these cells, such as, macrophages and neutrophils can
also express DR3. There was, however, no correlation
between levels of MMP-9, either in the PVAT or aortic
wall, and alterations in the constriction response irrespec-
tive of the presence or absence of DR3, suggesting that
MMP-9 has no dominant role in regulating vascular dys-
function.
Perhaps most significantly with regard to function,
inflammation and/or DR3 expression altered the cellular
composition of either the aortic vessel wall or PVAT. In
the absence of inflammation, while leukocyte numbers in
the aortic wall remained unchanged, DR3/ PVAT
showed increased total leukocyte counts, suggesting that
DR3 intrinsically controls the cellular content within the
PVAT. A more detailed analysis will be required to deter-
mine: firstly, which cell populations were increased (they
cannot be macrophages as the F4/80 signal remained
unchanged) and secondly, which DR3-dependent mecha-
nism(s) drive this homeostatic function. As its name sug-
gests, DR3 can induce apoptosis in vitro (Kitson et al.
1996); (Marsters et al. 1996), and in vivo (Wang et al.
2001); (Al-Lamki et al. 2008) but the majority of its phys-
iological functions are associated with proliferation, dif-
ferentiation, and effector cytokine release (Bamias et al.
2003); (Fang et al. 2008); (Meylan et al. 2008); (Pappu
et al. 2008); (Takedatsu et al. 2008); (Wang 2012); (Bull
et al. 2008) including the production of chemokines
(Kang et al. 2005); (Wang et al. 2014) that may attract or
release different subsets of cells. All of these processes can
alter the cellular composition of a tissue. Irrespective, this
is the first time a homeostatic role for DR3 on cell con-
tent of a nonimmune tissue has been described.
Systemic inflammation itself, regardless of DR3 expres-
sion, was associated with alterations in tissue composi-
tion. Thus, while the number of total cells within both
the aortic vessel wall and PVAT were unchanged,
increased F4/80+ expression suggests rising macrophage
numbers, but a concomitant decrease in as yet unidenti-
fied cell subsets within the tissue. Ablation of DR3 in an
inflammatory setting caused a further significant increase
in neutrophil numbers within the aortic cell wall.
Whether these changes are enough in themselves to drive
the observed vascular dysfunctions is a question for
debate. However, it has already been established that
macrophages have multiple functions in the vasculature,
whether they are resident macrophages in the aorta
(Gerrity 1981) carrying out “normal” functions such as
tissue remodeling (Fantin et al. 2010), or infiltrating
inflammatory macrophages that produce a complex
mixture of chemokines and adhesion molecules that
induce inflammation (Wellen and Hotamisligil 2003);
(Permana et al. 2006). Although more work would be
required to determine the specific macrophage pheno-
types within the PVAT, and how changes to these pheno-
types would impact the vascular constriction response, we
can speculate on the type of macrophages that may be
present. As we see a protective role of PVAT in DR3/,
where numbers of macrophages are increased, we would
expect to see an increase in M2 – anti-inflammatory
macrophages (Murray and Wynn 2011). While this does
not necessarily mean there will not be any M1 – pro-
inflammatory macrophages present, it is likely that the
balance has switched toward being M2 dominant. The
relationship between M1 and M2 macrophages in PVAT
has recently been evaluated. Ruan et al. (2015) showed
how a decrease in M1, coupled with an increase in M2
ameliorates vascular injury. Moreover, it is also possible
that increased production of IL-10 by M2 macrophages
underlies the protective effect of the PVAT (Weisser et al.
2013). IL-10 is a potent anti-inflammatory protein, and
while knocking out the IL-10 gene has no impact on vas-
cular constriction in healthy mice, following an inflam-
matory stimuli ablation of IL-10 exacerbates vascular
contractile dysfunction (Gunnett et al. 1999). Similarly,
experimental data from human studies has shown that
neutrophils can produce an endothelium-derived relaxing
factor-like product, causing vasorelaxation (Mehta et al.
1991) and both cell types can be induced to produce
nitric oxide.
One other subset of immune cells is worthy of mention
in the context of DR3, their presence in adipose tissue,
involvement in controlling inflammation, and therefore
the potential to influence vascular responses. Fat-resident
regulatory T cell (fTreg) modulate the inflammatory state
of adipose tissue and are reduced in murine models of
obesity (Feuerer 2009) where a clear decrease in vascular
function is evident (Stapleton et al. 2008). Interestingly,
DR3 is constitutively expressed on Treg (Twohig et al.
2012), and signaling through TL1A promotes their prolif-
eration (Meylan et al. 2011); (Shih et al. 2011); (Taraban
et al. 2011). Indeed, Treg expansion driven by hexameric
TL1A can protect against allergic lung inflammation and
has been trailed in models of transplant tolerance (Khan
et al. 2013). It is tempting to speculate that DR3/
PVAT would have impaired fTreg numbers or function,
which could impact on the ability of this tissue to regu-
late vascular constriction in an inflammatory setting.
Despite there being no currently published data sug-
gesting a link between DR3 expression and the produc-
tion of specialized pro-resolving mediators (SPM), we
postulate the potential for the two systems to be linked.
Focusing specifically on a subset of SPM known as
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lipoxins, that play a critical role in resolving local tissue
inflammation and maintaining homeostasis, it is possible
that they promote macrophage-driven uptake of neu-
trophils found in inflammatory sites (Godson et al.
2000). We postulate that this signal may be lost in our
DR3/ colony since in both the aortic vessel wall and
PVAT we see increased neutrophil numbers in compar-
ison to DR3 WT. Further studies are required to deter-
mine the role of this potential link.
In summary, the data presented here suggest that aortic
vascular dysfunction is driven by changes in the inflam-
matory status of the vasculature and PVAT. Alterations in
numbers of macrophages and neutrophils in both regions
are associated with the observed contractile changes. The
ablation of DR3 is protective against arthritis, but does
not diminish the associated systemic effects seen in the
vasculature. The importance of the PVAT is highlighted
as despite inflammatory changes, this tissue is protective
of normal vascular function. However, considerably more
work is required to understand the underlying mecha-
nisms controlling these processes.
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